Rezolute Q1 FY2025 net loss $15.4M; cash $117.8M; Phase 3 on track

Rezolute, Inc.

2025-Q1 EPS reported -$0.22

Net loss $15.4M vs $14.5M YoY; R&D $12.8M, G&A $4.2M.
Cash, equivalents, marketable securities $117.8M (Sep 30) vs $127.1M (Jun 30).
Phase 3 sunRIZE congenital HI enrollment on track; U.S. enrollment expected early 2025.
Tumor HI Phase 3 enrollment expected H1 2025; topline results H2 2026.
Topline sunRIZE results expected in second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.